Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer
Sponsor: Genta Incorporated
This PHASE2 trial investigates Adenocarcinoma of Esophagogastric Junction and Adenocarcinoma of the Stomach and is currently ongoing. Genta Incorporated leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genta Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .